World First Lung Cancer Vaccine Begins Testing
- Moderna Latest Study: mRNA Therapy for Treating T Cell-Mediated Autoimmune Diseases
- The Biosecure Act May Hurt Pharmaceutical Supply Chains
- Mosquito Elimination on Global Health: Unraveling the Claim of 700K Annual Deaths
- Intensive Blood Pressure Management to Below 140 mmHg Reduces Stroke Risk, Regardless of Medication Dosage
- GLP-1 Drugs: How Significant is Their Impact on Brain Health?
- Why Eel Sashimi Is Unsafe: Understanding the Risks of Consuming Raw Eel
World First Lung Cancer Vaccine Begins Testing
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
World First Lung Cancer Vaccine Begins Testing
The world’s first lung cancer vaccine has entered testing in several countries, including Spain, according to a report by Buenos Aires Economic News on August 24.
This medical milestone is considered by the scientific community to have groundbreaking potential, with hopes of saving hundreds of thousands of lives. Lung cancer claims nearly 1.8 million lives annually, making it the leading cause of cancer-related deaths worldwide. The low survival rate for advanced-stage lung cancer contributes to its high mortality.
The new vaccine, an mRNA (messenger ribonucleic acid) type, works by enabling the body to identify and destroy cancer cells while preventing their recurrence. Produced by the German company BioNTech, the vaccine is designed to treat non-small cell lung cancer, the most common form of lung cancer.
Named BNT116, the vaccine has entered Phase 1 clinical trials in seven countries: the United States, Germany, Spain, the United Kingdom, Poland, Hungary, and Turkey. A total of 130 patients have already been enrolled to receive the vaccine and undergo immunotherapy.
Similar to the COVID-19 vaccines, BNT116 uses mRNA technology. According to the U.S. National Cancer Institute, this type of vaccine “carries the genetic instructions needed to produce proteins, transferring this information from DNA in the cell nucleus to the cytoplasm where proteins are made.”
The vaccine works by presenting lung cancer tumor markers to the immune system, allowing the body to fight the cancer cells that express these markers. In essence, it serves as a form of “training” for the immune system. Unlike chemotherapy, this treatment enhances the immune system’s response without harming healthy cells.
University College London Hospitals (UCLH) is leading the trial in the UK. Professor Li Xiaoming, a consultant oncologist at UCLH, said, “We are entering an exciting new era of mRNA-based immunotherapy clinical trials for lung cancer treatment.”
Professor Li added, “The vaccine is easy to administer and can target specific antigens on cancer cells, then attack them.” Many experts agree that this technology represents the next significant phase in lung cancer treatment.
World First Lung Cancer Vaccine Begins Testing
______________________________
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
